GEORGE BROWN PRESS
JOURNALS, BOOKS & PROCEEDINGS

Journal of Medicine and Life Sciences

Article

Quality Control and Regulatory Standards for Controlled-Release Tablets: A Global Perspective

Lei Zhao [1,*], Na Chen [1] and Lei Wang [1]

[1] Zibo Wanjie Pharmaceutical Co. Ltd., Zibo, Shandong, China
* Correspondence: Lei Zhao, Zibo Wanjie Pharmaceutical Co. Ltd., Zibo, Shandong, China

Abstract: Controlled-release (CR) tablets play a crucial role in modern pharmaceutical formulations by enhancing therapeutic efficacy, reducing dosing frequency, and improving patient compliance. However, ensuring the quality and regulatory approval of these formulations remains a complex challenge due to variations in manufacturing processes, quality control parameters, and global regulatory requirements. This review provides a comprehensive analysis of CR tablet development, focusing on key formulation principles, quality control methodologies, and regional regulatory frameworks. It explores critical aspects such as dissolution testing, in vitro–in vivo correlation (IVIVC), and stability studies, highlighting the evolving role of artificial intelligence (AI) and emerging formulation technologies in optimizing drug release profiles. Furthermore, the review compares regulatory expectations across major regions, including the United States, European Union, China, and Japan, emphasizing the need for harmonized global standards. Addressing these challenges requires interdisciplinary collaboration to align regulatory requirements, enhance quality control precision, and foster innovation in controlled-release drug delivery.

Keywords: controlled-release tablets; quality control; dissolution testing; regulatory standards; in vitro–in vivo correlation (IVIVC)

1. Introduction

Controlled-release (CR) tablets have revolutionized modern drug delivery by offering precise and sustained drug release over extended periods. Unlike immediate-release formulations, which deliver the entire dose at once, controlled-release systems are designed to maintain therapeutic drug levels while minimizing fluctuations that may lead to adverse effects or reduced efficacy. These formulations play a crucial role in treating chronic conditions such as diabetes, hypertension, and psychiatric disorders, where maintaining stable plasma drug concentrations is essential for optimal therapeutic outcomes.

Ensuring the quality and performance of controlled-release tablets is paramount, as any deviation in formulation or manufacturing processes can significantly impact drug release profiles, bioavailability, and overall patient safety. Consequently, stringent quality control measures and regulatory oversight are necessary to ensure consistency, efficacy, and safety. Dissolution testing, stability studies, and in vitro–in vivo correlation (IVIVC) assessments are among the key quality control strategies employed to evaluate product performance before market approval [1].

Given the global nature of pharmaceutical markets, regulatory standards governing controlled-release formulations vary across different regions. The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), China's National Medical Products Administration (NMPA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) each impose distinct requirements for dissolution testing, bioequivalence studies, and manufacturing controls. Understanding these regulatory differences is essential for pharmaceutical companies aiming for global commercialization of controlled-release products.

Received: 19 March 2025
Revised: 26 March 2025
Accepted: 08 April 2025
Published: 11 April 2025

This review aims to provide a comprehensive analysis of quality control strategies and regulatory standards for controlled-release tablets from a global perspective. By comparing regulatory frameworks across major markets, this paper seeks to highlight key similarities, differences, and emerging trends that shape the future of controlled-release drug development and approval [2,3].

2. Fundamentals of Controlled-Release Tablets

2.1. Definition and Classification of Controlled-Release Formulations

Controlled-release (CR) tablets are pharmaceutical formulations designed to regulate the rate at which the active pharmaceutical ingredient (API) is released, thereby maintaining therapeutic drug levels over an extended period. Compared to immediate-release (IR) formulations, CR systems enhance patient compliance by reducing dosing frequency and minimizing plasma concentration fluctuations [4].

Controlled-release formulations can be classified based on their release mechanisms and design approaches. Table 1 summarizes the major types of controlled-release systems along with their key characteristics.

Table 1. Classification of Controlled-Release Formulations and Their Characteristics.

Type	Mechanism	Key Characteristics
Extended-release (ER)	Diffusion or dissolution control	Prolongs drug release to reduce dosing frequency
Sustained-release (SR)	Gradual drug diffusion	Provides continuous release to maintain therapeutic levels
Modified-release (MR)	Time-dependent or site-specific	Alters drug release profile (e.g., delayed, pulsatile)
Matrix-controlled	Polymer-based diffusion	Drug is embedded in a matrix, releasing over time
Reservoir systems	Membrane-controlled diffusion	Core drug reservoir surrounded by a rate-controlling membrane
Osmotic-controlled	Osmotic pressure	Water influx generates pressure, driving drug release

As shown in Table 1, the choice of a specific controlled-release system depends on the desired pharmacokinetic profile and therapeutic needs. These systems are designed to optimize drug absorption while minimizing side effects.

2.2. Mechanisms of Drug Release and Formulation Strategies

The controlled release of a drug is governed by various mechanisms, which determine the rate and extent of drug dissolution and absorption. The primary drug release mechanisms include:

Diffusion-controlled release: The drug diffuses through a polymer matrix or membrane at a controlled rate (e.g., matrix and reservoir systems).

Dissolution-controlled release: The release rate is determined by the dissolution of excipients or coating layers.

Osmotic-controlled release: A semipermeable membrane allows water to enter, creating osmotic pressure that drives drug release (as seen in osmotic pump systems, Table 1).

Erosion-controlled release: The drug is embedded in a biodegradable polymer that gradually erodes, allowing sustained release.

Ion-exchange systems: Drug release is controlled by ionic interactions between the API and ion-exchange resins.

To achieve these controlled-release effects, formulation strategies often incorporate hydrophilic or hydrophobic polymers (e.g., hydroxypropyl methylcellulose, ethylcellulose), lipid-based carriers, and multiparticulate systems.

2.3. Key Advantages and Challenges in Manufacturing

The development and manufacturing of controlled-release tablets offer several advantages but also present unique challenges.

2.3.1. Advantages

Enhanced patient compliance: Reduces the frequency of administration, improving adherence.

Improved therapeutic efficacy: Maintains stable plasma drug levels, preventing fluctuations.

Reduced side effects: Avoids high peak concentrations that may cause toxicity.

Optimized pharmacokinetics: Allows better absorption and bioavailability control.

2.3.2. Challenges

Complex formulation development: Requires precise control over API release kinetics and excipient interactions.

Manufacturing consistency: Ensuring batch-to-batch uniformity is critical for regulatory approval.

Dissolution and bioequivalence testing: Stringent regulatory requirements mandate extensive in vitro and in vivo testing.

Cost and scalability: Advanced materials and processing technologies increase production costs and complicate scale-up.

Despite these challenges, continuous advancements in material sciences and formulation technologies are driving innovation in controlled-release drug delivery. A deeper understanding of these mechanisms, as outlined in Table 1, allows for more precise formulation strategies and regulatory compliance [5].

3. Quality Control Parameters and Testing Methods

Ensuring the quality, efficacy, and safety of controlled-release (CR) tablets requires rigorous quality control testing. These tests assess the physicochemical properties, dissolution behavior, and stability of the formulation to meet regulatory standards. Key quality control parameters include physicochemical characterization, dissolution and release testing, and stability studies, all of which are crucial for regulatory approval and batch-to-batch consistency.

3.1. Physicochemical Characterization

Physicochemical properties of CR tablets must be thoroughly evaluated to ensure uniformity and mechanical strength. Critical parameters include uniformity of dosage units, tablet hardness, friability, thickness, and particle size distribution. Table 2 provides an overview of these parameters, their testing methods, and acceptance criteria.

Table 2. Physicochemical Characterization Parameters and Testing Methods.

Parameter	Testing Method	Acceptance Criteria
Uniformity of dosage units	Weight variation test; Content uniformity test	±10% deviation from the mean weight/content
Hardness	Tablet hardness tester (e.g., Monsanto tester)	Typically 4-10 kg for CR tablets
Friability	Roche friabilator	≤1% weight loss after rotation

Thickness	Vernier caliper/micrometer	Consistent with tablet specifications
Particle size distribution	Laser diffraction or sieve analysis	Uniform particle size to ensure controlled release

Physicochemical characterization ensures that CR tablets maintain their intended structural integrity and release profile throughout their shelf life. Deviations in these parameters may lead to altered dissolution rates, affecting therapeutic efficacy.

3.2. Dissolution and Release Testing

Dissolution testing is one of the most critical quality control steps for CR tablets, as it directly influences bioavailability and therapeutic outcomes. In vitro dissolution studies are used to evaluate drug release profiles and establish in vitro–in vivo correlation (IVIVC), which is essential for regulatory approval [6].

3.2.1. In Vitro Dissolution Studies and Bioequivalence

CR tablets must exhibit consistent and predictable dissolution profiles to ensure bioequivalence with reference formulations. Regulatory agencies, including the U.S. Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.), provide standardized dissolution testing protocols. These protocols assess whether the drug release follows the intended pharmacokinetic profile.

3.2.2. USP Apparatus for Dissolution Testing

Different types of USP dissolution apparatus are used based on the drug formulation and release mechanism. Table 3 summarizes the common dissolution testing apparatus and their applications.

Table 3. USP Dissolution Testing Apparatus and Their Applications.

USP Apparatus	Description	Application
Apparatus 1 (Basket)	Rotating basket method	Ideal for tablets that tend to float
Apparatus 2 (Paddle)	Rotating paddle method	Commonly used for CR tablets and capsules
Apparatus 3 (Reciprocating Cylinder)	Reciprocating movement in solution	Suitable for extended-release formulations
Apparatus 4 (Flow-Through Cell)	Continuous flow-through system	Used for poorly soluble drugs
Apparatus 5 (Paddle over Disk)	Paddle over a stationary disk	For transdermal formulations
Apparatus 6 (Cylinder)	Rotating cylinder	Modified for transdermal drug delivery

The selection of a dissolution apparatus depends on the dosage form and the drug's physicochemical properties. Among these, Apparatus 2 (Paddle Method) is the most widely used for CR tablets.

3.2.3. Mathematical Models for Release Kinetics

To analyze drug release profiles, various mathematical models are employed:

Zero-order kinetics: Drug release occurs at a constant rate, independent of concentration.

First-order kinetics: Drug release rate is proportional to the remaining drug concentration.

Higuchi model: Describes drug release from matrix systems based on diffusion.

Korsmeyer-Peppas model: Used to determine the mechanism of drug release from polymeric systems.

These models aid in predicting in vivo performance and optimizing formulation strategies.

3.3. Stability Studies

Stability testing ensures that CR tablets maintain their quality over time under various storage conditions. Regulatory guidelines, such as those from the International Council for Harmonisation (ICH Q1A(R2)), mandate accelerated and long-term stability studies to assess the impact of environmental factors on drug release [7].

Accelerated stability studies: Conducted under elevated temperature and humidity conditions (e.g., 40°C ± 2°C / 75% ± 5% RH) to predict the product's shelf life.

Long-term stability studies: Conducted under real-time storage conditions (e.g., 25°C ± 2°C / 60% ± 5% RH) to ensure prolonged stability.

Key stability parameters include drug potency, dissolution profile, moisture absorption, and excipient interactions. Variations in stability profiles may necessitate formulation modifications to maintain product efficacy.

4. Regulatory Standards Across Different Regions

The regulatory landscape for controlled-release (CR) tablets varies across different regions, with each regulatory authority imposing specific guidelines for formulation approval, quality control, and bioequivalence studies. While harmonization efforts by organizations such as the International Council for Harmonisation (ICH) and the World Health Organization (WHO) aim to align global standards, significant regional differences remain. This section provides an overview of key regulatory frameworks governing CR formulations in the United States, European Union, China, Japan, and other international jurisdictions.

4.1. FDA Regulations for Controlled-Release Drug Formulations

In the United States, the Food and Drug Administration (FDA) regulates controlled-release drug formulations under the Code of Federal Regulations (CFR) and the United States Pharmacopeia (USP). Specific guidance documents include the SUPAC-MR (Scale-Up and Post-Approval Changes for Modified Release Products), which outlines post-approval requirements for formulation changes [8].

Manufacturers seeking approval for CR tablets must submit either a New Drug Application (NDA) for innovative formulations or an Abbreviated New Drug Application (ANDA) for generic versions. ANDAs must demonstrate bioequivalence to the reference product through in vitro dissolution studies and, in some cases, in vivo pharmacokinetic studies. Table 4 summarizes key FDA regulations relevant to CR tablets.

Table 4. Key FDA Regulations and Guidance Documents for CR Tablets.

Regulation/Guidance	Description	Relevance to CR Tablets
USP General Chapters <711> & <724>	Establishes dissolution testing protocols	Specifies methods for controlled-release dosage forms
CFR Title 21, Part 320	Bioavailability and bioequivalence requirements	Defines criteria for bioequivalence studies
SUPAC-MR Guidance	Scale-up and post-approval changes for CR drugs	Outlines formulation modifications post-approval
ANDA Submission Guidelines	Requirements for generic drug approval	Mandates in vitro/in vivo correlation (IVIVC)

These regulations ensure that CR formulations in the U.S. maintain consistent drug release profiles, stability, and therapeutic efficacy

4.2. EMA Regulations for Controlled-Release Drug Formulations

The European Medicines Agency (EMA) oversees drug approval within the European Union. EMA guidelines for modified-release formulations align with European Pharmacopoeia (Ph. Eur.) standards, focusing on dissolution testing, bioequivalence studies, and risk assessment for formulation changes [9].

EMA mandates that CR formulations demonstrate dissolution profile similarity between test and reference products. Bioequivalence must be established through comparative f2 similarity factor analysis and, when necessary, pharmacokinetic studies.

4.3. NMPA Regulations for Controlled-Release Drug Formulations

In China, the National Medical Products Administration (NMPA) (formerly CFDA) regulates CR formulations under guidelines that share similarities with FDA and EMA requirements but also exhibit unique regulatory distinctions.

Unlike the U.S. and EU, China's regulatory framework places greater emphasis on local clinical trials for foreign-manufactured drugs. Additionally, NMPA requires extensive stability testing under China-specific climatic conditions, as detailed in Table 5.

Table 5. Key Differences in Regulatory Requirements for CR Tablets.

Regulatory Aspect	FDA (US)	EMA (EU)	NMPA (China)
Bioequivalence Testing	In vitro/in vivo correlation (IVIVC)	f2 similarity factor analysis	Requires additional local studies
Dissolution Testing	USP <711>, <724>	Ph. Eur. guidelines	CFDA/NMPA-specific protocols
Stability Testing	ICH Q1A(R2) guidelines	ICH-compliant, Ph. Eur. standards	China-specific climate conditions
Approval Pathways	NDA & ANDA	Centralized via EMA	Requires local Phase I trials

China's regulatory framework continues to evolve, incorporating more stringent quality control and post-market surveillance measures.

4.4. PMDA Regulations for Controlled-Release Drug Formulations

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) regulates CR formulations under guidelines aligned with ICH standards. PMDA approval requires extensive dissolution profile evaluation and compliance with Japanese Pharmacopoeia (JP) dissolution test specifications.

4.5. Other Regulatory Frameworks

Several international organizations contribute to harmonizing CR formulation standards worldwide:

World Health Organization (WHO): Issues prequalification standards for global pharmaceutical manufacturing.

ICH Guidelines (ICH Q6A, Q8, and Q9): Provide internationally recognized criteria for quality control, formulation development, and risk management.

5. Challenges and Future Perspectives

The development and regulation of controlled-release (CR) tablets are continuously shaped by scientific advancements and evolving regulatory frameworks. While these formulations offer significant therapeutic benefits, their manufacturing and approval processes present persistent challenges. Variability in regulatory requirements across different regions complicates global drug approval, while technological innovations such as

advanced dissolution testing and artificial intelligence (AI) in quality control redefine industry standards. This section explores these challenges and examines future directions that may drive the next generation of CR formulations [10].

5.1. Global Regulatory Variability and Its Implications

One of the foremost challenges in CR tablet development lies in the inconsistencies among regulatory agencies worldwide. While efforts have been made toward harmonization, significant differences persist in dissolution testing methodologies, bioequivalence requirements, and approval pathways. For instance, the U.S. Food and Drug Administration (FDA) places considerable emphasis on in vitro-in vivo correlation (IVIVC), often allowing manufacturers to demonstrate bioequivalence through dissolution studies, whereas regulatory bodies such as China's National Medical Products Administration (NMPA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) frequently require additional local pharmacokinetic studies. These differences necessitate distinct formulation strategies depending on the target market [11,12].

A comparative analysis of regulatory expectations (Table 6) highlights the impact of these variations on global drug approval. Differences in dissolution testing apparatus, stability study protocols, and approval mechanisms introduce additional complexity for multinational pharmaceutical companies. For example, the European Medicines Agency (EMA) mandates compliance with the European Pharmacopoeia, while the FDA follows United States Pharmacopeia (USP) standards, resulting in potential modifications in formulation design when seeking approval across jurisdictions.

Table 6. Key Regulatory Variations Impacting CR Tablet Approval.

Regulatory Factor	FDA (US)	EMA (EU)	NMPA (China)	PMDA (Japan)
Dissolution Testing	USP <711>, <724>	Ph. Eur. standards	CFDA/NMPA-specific	JP dissolution tests
Bioequivalence Studies	In vitro & in vivo (IVIVC)	f2 similarity factor	Requires local studies	Local pharmacokinetics
Stability Requirements	ICH Q1A(R2)	ICH-compliant	China-specific climate	ICH-aligned
Approval Pathways	ANDA/NDA	Centralized EMA approval	Local Phase I trials	PMDA-specific process

As evidenced by Table 6, these regulatory differences create hurdles for the pharmaceutical industry, requiring strategic planning to ensure compliance without excessive reformulation. The ongoing efforts by the International Council for Harmonisation (ICH) aim to standardize requirements, yet complete alignment remains elusive.

5.2. Advances in Dissolution Testing and IVIVC

Dissolution testing has long served as a critical tool in evaluating CR formulations, yet traditional methodologies often fail to fully predict in vivo drug performance. To address this, recent research has focused on refining dissolution media to better simulate human gastrointestinal conditions, incorporating elements such as bile salts and enzymatic activity to enhance predictive accuracy. Additionally, the application of mechanistic modeling techniques has enabled researchers to establish more reliable IVIVC, reducing reliance on clinical studies while maintaining regulatory confidence.

A significant breakthrough in this domain involves the adoption of biorelevant dissolution testing, which integrates dynamic pH changes and food effect simulations. These approaches, increasingly supported by regulatory agencies, provide a more comprehensive assessment of CR drug behavior post-ingestion. Nonetheless, achieving universal ac-

ceptance of such methodologies remains a challenge, as different agencies prioritize distinct testing parameters. The continued refinement of dissolution modeling, coupled with improved predictive computational algorithms, is expected to streamline formulation optimization and regulatory submissions in the near future.

5.3. Emerging Formulation Technologies and Their Regulatory Implications

As pharmaceutical sciences progress, novel formulation techniques are emerging to enhance the efficacy and precision of CR tablets. Among the most promising developments is the application of 3D printing technology, allowing precise control over drug release profiles through intricate matrix structures. This technique enables the fabrication of dosage forms with highly customizable dissolution characteristics, yet its large-scale adoption is hindered by regulatory uncertainties and manufacturing scalability concerns.

Additionally, advances in nanotechnology have opened new avenues for CR formulations, particularly in enhancing bioavailability and stability. The incorporation of stimuli-responsive polymers, capable of modulating drug release in response to environmental triggers such as pH or enzymatic activity, represents another frontier in formulation science. However, the regulatory pathways for such innovations remain underdeveloped, with agencies still adapting their evaluation criteria to accommodate these unconventional technologies.

5.4. The Role of AI and Machine Learning in Quality Control

Beyond formulation advancements, the integration of artificial intelligence (AI) and machine learning (ML) into quality control frameworks is reshaping pharmaceutical manufacturing. AI-driven predictive modeling enables real-time assessment of drug dissolution profiles, reducing batch failures and accelerating regulatory approval processes. Machine learning algorithms can also identify subtle variations in raw materials and process conditions, ensuring greater consistency in CR tablet production.

The impact of AI extends beyond manufacturing, influencing regulatory decision-making through advanced risk assessment models. By analyzing large datasets from clinical trials and dissolution studies, AI can identify patterns that inform bioequivalence assessments, potentially reducing the need for extensive in vivo testing. Although regulatory acceptance of AI-based methodologies remains in its early stages, ongoing collaborations between industry stakeholders and regulatory agencies are paving the way for its broader implementation.

6. Conclusion

The quality control and regulatory oversight of controlled-release (CR) tablets remain pivotal in ensuring their efficacy, safety, and market accessibility. This review has explored the fundamental principles of CR formulations, the diverse methodologies employed in quality control, and the complex regulatory landscapes governing their approval. A critical observation is the persistent variability in regulatory requirements across different regions, which complicates the global development and distribution of CR formulations. While efforts by organizations such as the International Council for Harmonisation (ICH) have contributed to greater alignment, significant disparities remain, particularly in bioequivalence assessment, dissolution testing protocols, and stability study requirements.

Future advancements in quality control methodologies are expected to further refine the evaluation of CR tablets. The integration of biorelevant dissolution testing, mechanistic modeling, and artificial intelligence (AI)-driven predictive analytics has the potential to enhance formulation accuracy, reduce reliance on in vivo studies, and expedite regulatory approvals. As these technologies gain wider acceptance, regulatory agencies must adapt their evaluation frameworks to accommodate novel testing methodologies, thereby fostering a more science-driven and efficient approval process.

A key factor in the global advancement of CR drug development is the establishment of harmonized regulatory standards. Divergent regulatory expectations not only impose additional costs on pharmaceutical manufacturers but also delay patient access to essential medications. Enhanced international cooperation among regulatory bodies will be crucial in addressing these challenges. Moving forward, a more unified approach—grounded in scientific consensus and technological advancements—can significantly streamline drug approval pathways, facilitating innovation while maintaining rigorous quality and safety standards.

In conclusion, the future of CR tablet development hinges on the industry's ability to balance regulatory compliance with technological progress. A concerted effort toward standardized quality control protocols, regulatory harmonization, and the adoption of emerging formulation technologies will be essential in driving the next generation of CR pharmaceuticals. By fostering greater collaboration between industry stakeholders and regulatory agencies, the pharmaceutical sector can achieve a more efficient, globally integrated framework that ultimately benefits both manufacturers and patients alike.

References

1. S. S. Hate, S. A. Thompson, and A. B. Singaraju, "Impact of sink conditions on drug release behavior of controlled-release formulations," *J. Pharm. Sci.*, vol. 114, no. 1, pp. 520-529, 2025, doi: 10.1016/j.xphs.2024.10.032.
2. P. Denduyver, C. Vervaet, and V. Vanhoorne, "Studying the API distribution of controlled-release formulations produced via continuous twin-screw wet granulation: Influence of matrix former, filler, and process parameters," *Pharmaceutics*, vol. 16, no. 3, p. 341, 2024, doi: 10.3390/pharmaceutics16030341
3. M. Sakkal et al., "Effect of hydration forms and polymer grades on theophylline controlled-release tablet: An assessment and evaluation," *Pharmaceuticals*, vol. 17, no. 3, p. 271, 2024, doi: 10.3390/ph17030271.
4. M. Tufail et al., "Controlled release bilayer floating effervescent and noneffervescent tablets containing levofloxacin and famotidine," *Int. J. Polym. Sci.*, vol. 2024, no. 1, p. 1243321, 2024, doi: 10.1155/2024/1243321.
5. S. S. Hate, S. A. Thompson, and A. B. Singaraju, "Impact of sink conditions on drug release behavior of controlled-release formulations," *J. Pharm. Sci.*, vol. 114, no. 1, pp. 520–529, 2025, doi: 10.1016/j.xphs.2024.10.032.
6. P. Denduyver, C. Vervaet, and V. Vanhoorne, "Studying the API distribution of controlled release formulations produced via continuous twin-screw wet granulation: Influence of matrix former, filler and process parameters," *Pharmaceutics*, vol. 16, no. 3, p. 341, 2024, doi: 10.3390/pharmaceutics16030341.
7. S. H. Seok, S. D. Yoo, and D. Kim, "Continuous manufacturing and process analytical technology: focusing on dosage forms with improved solubility and controlled release," *J. Pharm. Investig.*, 2025, doi: 10.1007/s40005-025-00732-y.
8. K. A. Khan et al., "Formulation and preparation of losartan-potassium-loaded controlled-release matrices using Ethocel grade 10 to establish a correlation between in vitro and in vivo results," *Pharmaceutics*, vol. 16, no. 2, p. 186, 2024, doi: 10.3390/pharmaceutics16020186.
9. P. Denduyver, C. Vervaet, and V. Vanhoorne, "The effect of fillerparticle size on API homogeneity of controlled release formulations via continuous twin-screw wet granulation," *Int. J. Pharm.*, vol. 669, p. 124990, 2025, doi: 10.1016/j.ijpharm.2024.124990.
10. M. Knarr, T. L. Rogers, O. Petermann, and R. Adden, "Investigation and rank-ordering of hydroxypropyl methylcellulose (HPMC) properties impacting controlled release performance," *J. Drug Deliv. Sci. Technol.*, vol. 104, p. 106425, 2025, doi: 10.1016/j.jddst.2024.106425.
11. M. Sakkal et al., "Preparation and characterization of theophylline controlled release matrix system incorporating poloxamer 407, stearyl alcohol, and hydroxypropyl methylcellulose: A novel formulation and development study," *Polymers*, vol. 16, no. 5, p. 643, 2024, doi: 10.3390/polym16050643.
12. K. Parmar, M. Patel, P. Bhatt, T. Soni, and B. Suhagia, "Optimization of HPMC loaded paroxetine HCl controlled release matrix tablet by central composite design," *Hacet. Univ. J. Fac. Pharm.*, vol. 44, no. 4, pp. 289–305, 2024, doi: 10.52794/hujpharm.1460738.